secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001725160-23-000148
Event type: other_material
Sentiment:  negative
Materiality: 0.40
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis shareholders reject advisory say-on-pay vote at 2023 annual meeting
----------------------------------------------------------------------------

- Advisory vote on executive compensation failed: 18.7M for, 34.3M against, 14K abstain.
- Amendment to certificate of incorporation updating officer exculpation provision approved (48.5M for).
- David Johnson and Jan Skvarka, Ph.D. elected as Class III directors with 38.6M and 52.5M votes for, respectively.
- Ratification of Ernst & Young as auditor approved with 55.7M votes for.
- 93.81% of outstanding shares represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000148/0001725160-23-000148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000148/zntl-20230616.htm
  HTML page:      https://secwatch.observer/filing/0001725160-23-000148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer